New Scoring System Available at Home Health Care for Prediction of 14 Days Survival in Lung Cancer Complicated with Lymphangitic Carcinomatosis

Satomi Konno1, Takuya Kishi2, Hideyuki Kashiwagi1, Takehiko Makino3 and Takeyuki Matsuguchi1

1Matsuguchi Clinic, Japan
2Department of Advanced Therapeutics for Cardiovascular Diseases, Kyushu University Graduate School of Medical Sciences, Japan
3Department of Palliative Care, Aso-Iizuka Hospital, Japan

Corresponding author: Takuya Kishi, Department of Advanced Therapeutics for Cardiovascular Diseases, Kyushu University Graduate School of Medical Sciences, 3-1-1 maidashi, higashi-ku, Fukuoka 812-8582, Japan, Tel: 81-92-842-5360; E-mail: tkishi@cardiol.med.kyushu-u.ac.jp

Received date: Sep 23, 2014, Accepted date: Nov 13, 2014, Published date: Nov 22, 2014

Abstract

Objective: Patients with lung cancer often greeted their terminal phase in the treatment at home, and many cases complicated with lymphangitic carcinomatosis took a sudden turn. The aim of the present study was to determine a scoring system available at home health care for prediction of short-term survival of lung cancer complicated with lymphangitic carcinomatosis.

Methods: In 14 lung cancer patients with lymphangitic carcinomatosis in our medical care at home, we determined significant close correlated and independent factors for assuming death during 14 days by logistic-regression analysis, and made out new scoring system. Moreover, we determined cut-off value on receiver-operating characteristics analysis.

Results: In our scoring system calculated as the summation points awarded for the presence of 5 parameters (i.e., systolic blood pressure<90 mmHg, 2 point; pulse rate>100 beats/minute, 3 point; blood oxygen saturation<90%, 3 point; oxygen dose>2 L/minute, 2 point; respiratory frequency>20 times/minute, 3 point), cut-off value was 8 (sensitivity 90%, specificity 68%).

Conclusions: We made a new a scoring system available at home health care for prediction of 14 days survival of lung cancer complicated with lymphangitic carcinomatosis assumed systolic blood pressure, pulse rate, respiratory frequency, blood oxygen saturation, and oxygen dose.

Keywords: Lung cancer; Lymphangitic carcinomatosis; Home health care; Survival

Introduction

Background

In our Iizuka city at Japan, aging has suddenly advances, because of lacking alternate industries for traditional coal industry. Moreover, we have so many households including only elderly people, as symbolizing the Japanese community, and it is necessary to do the home health care for end-stage illness, especially malignant cancer. In the aspect of home health care for end-stage, the remained survival would provide important and indispensability information to patients, oncology and palliative care to produce the meaningful remained days without excess anxiety for patients and to avoid inappropriate treatments [2].

Previous studies have already established the objective prediction for survival in patients with end-stage malignant cancer [3-8]. Maltoni et al. indicated that clinical survival prediction (clinical prediction of survival (CPS)) and prognostic scores are recommended (level A) based on evidence in the prognostic correlation within 90 days [3]. Stone et al. discussed Palliative Prognostic Score (PaP), Palliative Prognostic Index (PPI), terminal cancer prognostic (TCP) score, Bruera poor prognostic indicator, and Chang prognostic score (CPS), and concluded that the prognostic scales offer an improvement on unadjusted clinician estimates of survival, in spite of several limitations [3-8]. The PPI established as an objective 3 weeks prognosis estimated evaluation of the cancer in terminal phase is available at home health care without drawing blood. Interestingly, recent paper suggested that Prognosis in Palliative care Study without blood results could be performed as well as clinician' estimates of survival [9].

Lung cancer is most common in patients with cancer in our country. Therefore, patients with lung cancer often greeted their terminal phase in the treatment at home health care. At the start of the present study, we consecutively experienced the sudden and not anticipated death of lymphangitic carcinomatosis in such a period. However, we have no methods available at home health care to predict short-term survival of such patients. Therefore, the aim of the present study was to determine a scoring system available at home health care...
for prediction of short-term survival of lung cancer complicated with lymphangitic carcinomatosis.

Methods

Among the patients who took home health care of Matsuguchi Clinic between January 2010 and December 2012, 14 consecutive lung cancer patients with lymphangitic carcinomatosis were retrospectively enrolled. We defined 15 days survival as the primary outcome. Clinical parameters at the first visit to patient’s home after the initiation of home health care by our clinic were assessed, because our motivation was to determine the predictive tool of short-term survival at the first visit to patient’s home. Continuous variables were compared by unpaired t-test. Categorical variables were compared by Fischer’s exact test. Univariate and multivariate analysis with a logistic regression model were done to calculate adjusted odds ratio (OR) and 95% confidence interval (CI) to assess the influence of each variable to 15 days survival. Significant variables in the univariate analysis were assessed in the multivariable analysis. Weighed scores were allocated to each selected variable on the basis of each OR, and we made a new scoring system. Moreover, a cut-off point was obtained by receiver-operating characteristic (ROC) analysis with SPSS (SPSS Inc., Chicago, IL, U.S.A.). A ROC curve was made by which the area under the curve (AUC) for the score was calculated. All data are expressed as mean ± standard deviation. Significance was regarded as P<0.05. The present study complied with the Declaration of Helsinki. Informed consent was obtained from all patients before enrollment.

Results

Among the enrolled 14 patients (10 males and 4 females, mean age was 67 ± 3 years), 6 patients (5 males and 1 female, mean age was 69 ± 5 years) died within 15 days at home. Table 1 showed the clinical parameters at the first visit to patient’s home after the initiation of home health care by our clinic.

Table 1: *P<0.05 vs. patients with survival over 15 days (SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; bpm: beats per minute; RF: respiratory frequency).

In the univariable analysis, a significant difference was found in systolic blood pressure<90 mmHg, pulse rate>100 beats/minute, blood oxygen saturation<90%, oxygen dose>2 L/minute, respiratory frequency>20 times/minute (Table 2). According to the multivariable analysis, systolic blood pressure<90 mmHg, pulse rate>100 beats/minute, blood oxygen saturation<90%, oxygen dose>2 L/minute, respiratory frequency>20 times/minute were independent factors for 14 days survival (Table 2).

Table 2: Univariate and Multivariate analysis (SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; bpm: beats per minute).

Figure 1: ROC curve of our scoring system for the prediction of 14 days survival of lung cancer with lymphangitis carcinomatosis. Sensitivity and specificity of each cutoff points are shown.


Discussion

In the present study, we made a new a scoring system for prediction of 14 days survival of lung cancer complicated with lymphangitic carcinomatosis assumed systolic blood pressure, pulse rate, respiratory frequency, blood oxygen saturation, and oxygen dose. Cut-off value of summation points awarded for the presence of 5 parameters (systolic blood pressure<90 mmHg, 2 point; pulse rate>100 beats/minute, 3 point; blood oxygen saturation<90%, 3 point; oxygen dose>2 L/minute, 2 point; respiratory frequency>20 times/minute, 3 point) was 8 (90% of sensitivity, specificity 68%) by ROC analysis.

Previous studies have demonstrated that the survival of malignant cancer can be predicted significantly by decrease in false cholinesterase [3,10], increase in vitamin B12 [3,11], increase in serum bilirubin [3,12], increase in lymphocytes [3,5,10], and increase in leukocytosis [5,10] statistically. However, these parameters are assessed by blood sample, and are not easily used in home health care. In these aspects, our present results and scoring system have clinical implications. Furthermore, it will be certain that wearing devices of body monitoring would spread by medical innovation in future, and the present scoring system could be calculated automatically at home health care by the future wearing medical devices without the visiting of medical staff.

Limitation and Strengths

The present study is just only a biased retrospective assessment at a single center, and the statistic power is not so high. Moreover, the sample size per 3 years was small, because we focused only lymphangitic carcinomatosis, which is not major in lung cancer overall. Not only lymphangitic carcinomatosis, the patients who had advanced stages of lung cancer could have suffered from many kinds of symptoms and conditions. Moreover, we used the parameters only assessed at the first visit to patient’s home after the initiation of home health care by out clinic, because out motivation was to determine the predictive tool of short-term survival at the first visit to patient’s home. We did not assess the time course of clinical parameters as predictive value. Considering these limitations, we could not provide our scoring system as a useful definitive predictive tool in clinical practice for lung cancer from only the present results.

The study’s greatest strength is that we tried to make a new and potentiated scoring system available at home health care for prediction of 14 days survival of lung cancer complicated with lymphangitic carcinomatosis assumed systolic blood pressure, pulse rate, respiratory frequency, blood oxygen saturation, and oxygen dose. Next future prospective large and multi-center studies are necessary to determine whether our concept would be really useful in clinical practice for lung cancer.

Acknowledgement

The Department of Advanced Therapeutics for Cardiovascular Diseases, Kyushu University Graduate School of Medical Sciences, is supported by Otsuka Pharma and Nippon Boehringer Ingelheim (to Dr. Kishi). We would like to make special thanks to all the medical staff of Matsuguchi Clinic.

References